Dr. Elisabeth Heath, MD

Internal Medicine Rochester, MN Female
NPI: 1700823796
Total Payments
$278,746
2024 Payments
$16,897
Companies
23
Transactions
205
Medicare Patients
1,227
Medicare Billing
$163,520

Payment Breakdown by Category

Consulting$138,556 (49.7%)
Other$106,959 (38.4%)
Travel$17,304 (6.2%)
Research$12,240 (4.4%)
Food & Beverage$3,652 (1.3%)
Education$35.32 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $138,556 46 49.7%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $105,459 38 37.8%
Travel and Lodging $17,304 52 6.2%
Unspecified $12,240 7 4.4%
Food and Beverage $3,652 60 1.3%
Honoraria $1,500 1 0.5%
Education $35.32 1 0.0%

Payments by Type

General
$266,506
198 transactions
Research
$12,240
7 transactions

Top Paying Companies

Company Total Records Latest Year
GENZYME CORPORATION $117,012 82 $0 (2023)
PFIZER INC. $27,045 12 $0 (2024)
Bayer Healthcare Pharmaceuticals Inc. $20,961 18 $0 (2024)
AstraZeneca UK Limited $20,550 4 $0 (2023)
AstraZeneca Pharmaceuticals LP $13,518 10 $0 (2021)
Seattle Genetics, Inc. $12,733 25 $0 (2019)
Novartis Pharmaceuticals Corporation $12,410 6 $0 (2024)
Celgene Corporation $9,705 5 $0 (2019)
Seagen Inc. $9,006 6 $0 (2023)
EMD Serono, Inc. $7,125 1 $0 (2023)

Payment History by Year

Year Amount Transactions Top Company
2024 $16,897 7 Novartis Pharmaceuticals Corporation ($8,119)
2023 $29,722 17 EMD Serono, Inc. ($7,125)
2022 $50,046 24 GENZYME CORPORATION ($28,934)
2021 $36,241 17 AstraZeneca Pharmaceuticals LP ($9,470)
2020 $29,354 16 GENZYME CORPORATION ($8,211)
2019 $68,266 83 GENZYME CORPORATION ($35,274)
2018 $18,222 17 GENZYME CORPORATION ($14,593)
2017 $29,997 24 GENZYME CORPORATION ($16,214)

All Payment Transactions

205 individual payment records from CMS Open Payments — Page 1 of 9

Date Company Product Nature Form Amount Type
09/24/2024 Novartis Pharmaceuticals Corporation PLUVICTO (Drug) Consulting Fee Cash or cash equivalent $4,400.00 General
Category: Oncology
07/03/2024 Bayer Healthcare Pharmaceuticals Inc. — Consulting Fee Cash or cash equivalent $2,808.00 General
06/13/2024 Bayer Healthcare Pharmaceuticals Inc. Nubeqa (Drug), Xofigo Consulting Fee Cash or cash equivalent $2,106.00 General
Category: Oncology
06/07/2024 Novartis Pharmaceuticals Corporation PLUVICTO (Drug) — Cash or cash equivalent $2,118.71 Research
Study: HEOR • Category: Oncology
05/07/2024 Novartis Pharmaceuticals Corporation — Consulting Fee Cash or cash equivalent $1,600.00 General
03/08/2024 PFIZER INC. ORGOVYX (Drug) Travel and Lodging In-kind items and services $705.75 General
Category: ONCOLOGY
02/09/2024 Bayer Healthcare Pharmaceuticals Inc. — Consulting Fee Cash or cash equivalent $3,159.00 General
12/26/2023 PFIZER INC. ORGOVYX (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $3,900.00 General
Category: ONCOLOGY
12/13/2023 GENZYME CORPORATION JEVTANA (Drug) Consulting Fee Cash or cash equivalent $1,862.50 General
Category: Oncology
12/12/2023 Bayer Healthcare Pharmaceuticals Inc. Nubeqa (Drug) Consulting Fee Cash or cash equivalent $351.00 General
Category: Oncology
12/08/2023 PFIZER INC. ORGOVYX (Drug) Travel and Lodging In-kind items and services $667.91 General
Category: ONCOLOGY
12/08/2023 PFIZER INC. ORGOVYX (Drug) Food and Beverage In-kind items and services $48.88 General
Category: ONCOLOGY
12/05/2023 EMD Serono, Inc. — Consulting Fee Cash or cash equivalent $7,125.00 General
11/29/2023 Gilead Sciences, Inc. Trodelvy (Drug) Consulting Fee Cash or cash equivalent $2,390.00 General
Category: ONC
11/17/2023 Gilead Sciences, Inc. Trodelvy (Drug) Food and Beverage In-kind items and services $41.54 General
Category: ONC
11/16/2023 Seagen Inc. PADCEV (Biological) Food and Beverage In-kind items and services $48.90 General
Category: Oncology
08/18/2023 Sumitomo Pharma America, Inc. ORGOVYX (Drug) Food and Beverage In-kind items and services $16.59 General
Category: HORMONE THERAPY
07/17/2023 AstraZeneca UK Limited — Consulting Fee Cash or cash equivalent $2,055.00 General
03/29/2023 GENZYME CORPORATION — Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $2,524.00 General
03/20/2023 Astellas Pharma Global Development Xtandi (Drug) Consulting Fee Cash or cash equivalent $1,875.00 General
Category: Oncology
02/15/2023 NOVARTIS PHARMACEUTICALS CORPORATION PLUVICTO (Drug) Consulting Fee Cash or cash equivalent $4,000.00 General
Category: Oncology
02/15/2023 NOVARTIS PHARMACEUTICALS CORPORATION PLUVICTO (Drug) Travel and Lodging Cash or cash equivalent $199.53 General
Category: Oncology
02/15/2023 NOVARTIS PHARMACEUTICALS CORPORATION PLUVICTO (Drug) Food and Beverage In-kind items and services $91.89 General
Category: Oncology
01/06/2023 GENZYME CORPORATION — Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $2,524.00 General
12/22/2022 Myovant Sciences Inc. ORGOVYX (Drug) Food and Beverage In-kind items and services $19.41 General
Category: HORMONE THERAPY
123…9»

Research Studies & Clinical Trials

Study Name Company Amount Records
AZA-ST-001 - A Phase 1 Study of CC-486 as a Single Agent and in Combination with Carboplatin or ABI-007 in Subjects with Relapsed or Refractory Solid Tumors Celgene Corporation $3,444 1
ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM PFIZER INC. $3,200 1
AZA-ST-001 Celgene Corporation $2,533 1
HEOR Novartis Pharmaceuticals Corporation $2,119 1
A PHASE 1 STUDY OF THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF ASG-22CE GIVEN AS MONOTHERAPY IN SUBJECTS WITH METASTATIC UROTHELIAL CANCER AND OTHER MALIGNANT SOLID TUMORS THAT EXPRESS NECTIN-4 Astellas Pharma Global Development $852.50 1
A single-arm, open-label, multicenter study of enfortumab vedotin ASG-22CE for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor CPI therapy Seattle Genetics, Inc. $92.03 2

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 4 255 482 $98,990 $31,957
2022 5 312 690 $133,952 $45,103
2021 5 319 737 $144,132 $49,484
2020 5 341 697 $180,746 $36,977
Total Patients
1,227
Total Services
2,606
Medicare Billing
$163,520
Procedure Codes
30

All Medicare Procedures & Services

30 procedure records from CMS Medicare Utilization — Page 1 of 2

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2023 68 154 $34,804 $11,558 33.2%
99213 Established patient office or other outpatient visit, 20-29 minutes Facility 2023 75 144 $22,464 $7,126 31.7%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2023 33 67 $15,142 $4,887 32.3%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2023 43 81 $12,636 $3,786 30.0%
99205 New patient office or other outpatient visit, 60-74 minutes Facility 2023 12 12 $5,220 $1,768 33.9%
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2023 13 13 $3,939 $1,504 38.2%
99205 New patient office or other outpatient visit, 60-74 minutes Office 2023 11 11 $4,785 $1,327 27.7%
99213 Established patient office or other outpatient visit, 20-29 minutes Facility 2022 108 301 $46,956 $15,798 33.6%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2022 57 130 $29,380 $10,240 34.9%
99213 Established patient office or other outpatient visit, 20-29 minutes Office 2022 57 147 $22,932 $7,250 31.6%
99214 Established patient office or other outpatient visit, 30-39 minutes Office 2022 31 52 $11,752 $3,831 32.6%
99205 New patient office or other outpatient visit, 60-74 minutes Facility 2022 24 24 $10,440 $3,476 33.3%
99205 New patient office or other outpatient visit, 60-74 minutes Office 2022 13 13 $5,655 $1,968 34.8%
99215 Established patient office or other outpatient visit, 40-54 minutes Office 2022 11 12 $3,636 $1,431 39.4%
99222 Initial hospital inpatient care per day, typically 50 minutes Facility 2022 11 11 $3,201 $1,109 34.7%
99213 Established patient outpatient visit, total time 20-29 minutes Facility 2021 110 361 $56,316 $19,005 33.7%
99214 Established patient outpatient visit, total time 30-39 minutes Facility 2021 59 106 $23,900 $8,247 34.5%
99213 Established patient outpatient visit, total time 20-29 minutes Office 2021 40 125 $19,500 $6,861 35.2%
99214 Established patient outpatient visit, total time 30-39 minutes Office 2021 36 67 $15,142 $5,366 35.4%
99205 New patient outpatient visit, total time 60-74 minutes Facility 2021 29 29 $12,615 $3,948 31.3%
99215 Established patient outpatient visit, total time 40-54 minutes Facility 2021 17 20 $6,060 $2,387 39.4%
99205 New patient outpatient visit, total time 60-74 minutes Office 2021 15 15 $6,525 $2,199 33.7%
99222 Initial hospital inpatient care, typically 50 minutes per day Facility 2021 13 14 $4,074 $1,471 36.1%
99213 Established patient office or other outpatient visit, typically 15 minutes Facility 2020 136 332 $70,736 $12,956 18.3%
99214 Established patient office or other outpatient, visit typically 25 minutes Facility 2020 97 198 $59,412 $12,674 21.3%
12»

About Dr. Elisabeth Heath, MD

Dr. Elisabeth Heath, MD is a Internal Medicine healthcare provider based in Rochester, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700823796.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Elisabeth Heath, MD has received a total of $278,746 in payments from pharmaceutical and medical device companies, with $16,897 received in 2024. These payments were reported across 205 transactions from 23 companies. The most common payment nature is "Consulting Fee" ($138,556).

As a Medicare-enrolled provider, Heath has provided services to 1,227 Medicare beneficiaries, totaling 2,606 services with total Medicare billing of $163,520. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.

Practice Information

  • Specialty Internal Medicine
  • Other Specialties Medical Oncology, Medical Oncology
  • Location Rochester, MN
  • Active Since 05/31/2006
  • Last Updated 12/16/2024
  • Taxonomy Code 207R00000X
  • Entity Type Individual
  • NPI Number 1700823796

Products in Payments

  • JEVTANA (Drug) $94,020
  • XTANDI (Drug) $18,722
  • LYNPARZA (Drug) $14,728
  • Nubeqa (Drug) $13,051
  • PLUVICTO (Drug) $10,810
  • ORGOVYX (Drug) $8,394
  • PADCEV (Biological) $7,626
  • CC-486 (Drug) $5,977
  • Erleada (Drug) $5,389
  • CABOMETYX (Drug) $3,960
  • CC-90011 (Drug) $3,728
  • OPDIVO (Biological) $2,700
  • Trodelvy (Drug) $2,432
  • PROVENGE (Drug) $2,156
  • Xofigo (Drug) $1,944
  • Xtandi (Drug) $1,875
  • FYARRO (Drug) $1,500
  • PADCEV (Drug) $852.50
  • NO PRODUCT DISCUSSED (Drug) $849.13
  • Axumin (Drug) $142.24

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Internal Medicine Doctors in Rochester

Dr. Ben George, M.d, M.D

Internal Medicine — Payments: $729,795

Internal Medicine $729,795

John Kisiel, M.d, M.D

Internal Medicine — Payments: $550,377

Internal Medicine $550,377

Gregory Poland, M.d, M.D

Internal Medicine — Payments: $532,099

Internal Medicine $532,099

Christopher Ritchlin, Md, MD

Internal Medicine — Payments: $512,889

Internal Medicine $512,889

Scott Feitell, D.o, D.O

Internal Medicine — Payments: $471,187

Internal Medicine $471,187

Prashant Kapoor, Md, MD

Internal Medicine — Payments: $403,295

Internal Medicine $403,295